azilsartan medoxomil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| angiotensin II receptor antagonists, antihypertensive (non-peptidic) | 4322 | 863031-21-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an angiotensin type 1 receptor blocker; receptor blocker
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 40 | mg | O |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 25, 2011 | FDA | ARBOR PHARMS IRELAND |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Renal failure | 39.27 | 38.83 | 11 | 108 | 17338 | 2340628 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C09CA09 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain |
| ATC | C09DA09 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics |
| FDA MoA | N0000180999 | Angiotensin 2 Type 1 Receptor Antagonists |
| FDA EPC | N0000175561 | Angiotensin 2 Receptor Blocker |
| FDA PE | N0000178477 | Decreased Blood Pressure |
| MeSH PA | D047228 | Angiotensin II Type 1 Receptor Blockers |
| MeSH PA | D057911 | Angiotensin Receptor Antagonists |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:61016 | angiotensin receptor antagonist |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Hypovolemia | contraindication | 28560003 | |
| Low blood pressure | contraindication | 45007003 | |
| Hyponatremia | contraindication | 89627008 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Pregnancy, function | contraindication | 289908002 | |
| Renal artery stenosis | contraindication | 302233006 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.11 | acidic |
| pKa2 | 3.02 | Basic |
| pKa3 | 2.4 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 40MG MEDOXOMIL | EDARBI | ARBOR PHARMS LLC | N200796 | Feb. 25, 2011 | RX | TABLET | ORAL | 7572920 | Jan. 7, 2025 | TREATMENT OF HYPERTENSION |
| EQ 80MG MEDOXOMIL | EDARBI | ARBOR PHARMS LLC | N200796 | Feb. 25, 2011 | RX | TABLET | ORAL | 7572920 | Jan. 7, 2025 | TREATMENT OF HYPERTENSION |
| EQ 40MG MEDOXOMIL | EDARBYCLOR | ARBOR PHARMS LLC | N202331 | Dec. 20, 2011 | RX | TABLET | ORAL | 7572920 | Jan. 7, 2025 | TREATMENT OF HYPERTENSION |
| EQ 40MG MEDOXOMIL | EDARBYCLOR | ARBOR PHARMS LLC | N202331 | Dec. 20, 2011 | RX | TABLET | ORAL | 9387249 | July 1, 2031 | TREATMENT OF HYPERTENSION |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Type-1 angiotensin II receptor | GPCR | ANTAGONIST | UNKNOWN | CHEMBL | |||||
| Type-1 angiotensin II receptor | GPCR | IC50 | 6.38 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| C2979837 | UMLSCUI |
| D08067 | KEGG_DRUG |
| 013662 | NDDF |
| 27787 | MMSL |
| 4030594 | VANDF |
| 449561004 | SNOMEDCT_US |
| 1091642 | RXNORM |
| CHEMBL57242 | ChEMBL_ID |
| F9NUX55P23 | UNII |
| 8724 | INN_ID |
| 147403-03-0 | SECONDARY_CAS_RN |
| C521273 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB08822 | DRUGBANK_ID |
| CHEBI:68845 | CHEBI |
| 6900 | IUPHAR_LIGAND_ID |
| CHEMBL2028661 | ChEMBL_ID |
| CHEMBL2103795 | ChEMBL_ID |
| 135409642 | PUBCHEM_CID |
| C557413 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
None